TY - JOUR
T1 - Diosgenin
T2 - An Updated Pharmacological Review and Therapeutic Perspectives
AU - Semwal, Prabhakar
AU - Painuli, Sakshi
AU - Abu-Izneid, Tareq
AU - Rauf, Abdur
AU - Sharma, Anshu
AU - Daştan, Sevgi Durna
AU - Kumar, Manoj
AU - Alshehri, Mohammed M.
AU - Taheri, Yasaman
AU - Das, Rajib
AU - Mitra, Saikat
AU - Emran, Talha Bin
AU - Sharifi-Rad, Javad
AU - Calina, Daniela
AU - Cho, William C.
N1 - Publisher Copyright:
© 2022 Prabhakar Semwal et al.
PY - 2022
Y1 - 2022
N2 - Plants including Rhizoma polgonati, Smilax china, and Trigonella foenum-graecum contain a lot of diosgenin, a steroidal sapogenin. This bioactive phytochemical has shown high potential and interest in the treatment of various disorders such as cancer, diabetes, arthritis, asthma, and cardiovascular disease, in addition to being an important starting material for the preparation of several steroidal drugs in the pharmaceutical industry. This review aims to provide an overview of the in vitro, in vivo, and clinical studies reporting the diosgenin's pharmacological effects and to discuss the safety issues. Preclinical studies have shown promising effects on cancer, neuroprotection, atherosclerosis, asthma, bone health, and other pathologies. Clinical investigations have demonstrated diosgenin's nontoxic nature and promising benefits on cognitive function and menopause. However, further well-designed clinical trials are needed to address the other effects seen in preclinical studies, as well as a better knowledge of the diosgenin's safety profile.
AB - Plants including Rhizoma polgonati, Smilax china, and Trigonella foenum-graecum contain a lot of diosgenin, a steroidal sapogenin. This bioactive phytochemical has shown high potential and interest in the treatment of various disorders such as cancer, diabetes, arthritis, asthma, and cardiovascular disease, in addition to being an important starting material for the preparation of several steroidal drugs in the pharmaceutical industry. This review aims to provide an overview of the in vitro, in vivo, and clinical studies reporting the diosgenin's pharmacological effects and to discuss the safety issues. Preclinical studies have shown promising effects on cancer, neuroprotection, atherosclerosis, asthma, bone health, and other pathologies. Clinical investigations have demonstrated diosgenin's nontoxic nature and promising benefits on cognitive function and menopause. However, further well-designed clinical trials are needed to address the other effects seen in preclinical studies, as well as a better knowledge of the diosgenin's safety profile.
UR - https://www.scopus.com/pages/publications/85131396021
U2 - 10.1155/2022/1035441
DO - 10.1155/2022/1035441
M3 - Artículo de revisión
C2 - 35677108
AN - SCOPUS:85131396021
SN - 1942-0900
VL - 2022
JO - Oxidative Medicine and Cellular Longevity
JF - Oxidative Medicine and Cellular Longevity
M1 - 1035441
ER -
